栄研化学の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/03/10 | 1,742 | 1,748 | 1,730 | 1,742 | +40 | +2.4% | 71,300 |
| 2022/03/09 | 1,703 | 1,718 | 1,679 | 1,702 | -1 | -0.1% | 103,500 |
| 2022/03/08 | 1,698 | 1,737 | 1,693 | 1,703 | +3 | +0.2% | 103,300 |
| 2022/03/07 | 1,698 | 1,710 | 1,664 | 1,700 | -10 | -0.6% | 113,400 |
| 2022/03/04 | 1,735 | 1,736 | 1,710 | 1,710 | -12 | -0.7% | 71,300 |
| 2022/03/03 | 1,770 | 1,770 | 1,722 | 1,722 | -16 | -0.9% | 82,900 |
| 2022/03/02 | 1,751 | 1,756 | 1,733 | 1,738 | -30 | -1.7% | 90,100 |
| 2022/03/01 | 1,752 | 1,774 | 1,746 | 1,768 | +28 | +1.6% | 87,100 |
| 2022/02/28 | 1,699 | 1,740 | 1,693 | 1,740 | +30 | +1.8% | 123,100 |
| 2022/02/25 | 1,691 | 1,714 | 1,686 | 1,710 | +11 | +0.6% | 138,700 |
| 2022/02/24 | 1,711 | 1,735 | 1,688 | 1,699 | -17 | -1% | 122,500 |
| 2022/02/22 | 1,719 | 1,725 | 1,700 | 1,716 | -23 | -1.3% | 86,400 |
| 2022/02/21 | 1,728 | 1,745 | 1,721 | 1,739 | -17 | -1% | 64,800 |
| 2022/02/18 | 1,720 | 1,759 | 1,718 | 1,756 | +13 | +0.7% | 62,800 |
| 2022/02/17 | 1,771 | 1,777 | 1,743 | 1,743 | -33 | -1.9% | 84,100 |
| 2022/02/16 | 1,790 | 1,794 | 1,766 | 1,776 | +20 | +1.1% | 90,400 |
| 2022/02/15 | 1,785 | 1,796 | 1,751 | 1,756 | -33 | -1.8% | 106,100 |
| 2022/02/14 | 1,802 | 1,806 | 1,782 | 1,789 | -49 | -2.7% | 115,600 |
| 2022/02/10 | 1,840 | 1,842 | 1,825 | 1,838 | +4 | +0.2% | 74,500 |
| 2022/02/09 | 1,823 | 1,841 | 1,805 | 1,834 | +28 | +1.6% | 138,900 |
| 2022/02/08 | 1,803 | 1,827 | 1,801 | 1,806 | +18 | +1% | 146,300 |
| 2022/02/07 | 1,795 | 1,804 | 1,771 | 1,788 | -8 | -0.4% | 131,100 |
| 2022/02/04 | 1,805 | 1,815 | 1,771 | 1,796 | +5 | +0.3% | 130,700 |
| 2022/02/03 | 1,762 | 1,802 | 1,751 | 1,791 | +23 | +1.3% | 165,000 |
| 2022/02/02 | 1,709 | 1,775 | 1,707 | 1,768 | +82 | +4.9% | 286,700 |
| 2022/02/01 | 1,735 | 1,759 | 1,684 | 1,686 | -25 | -1.5% | 249,400 |
| 2022/01/31 | 1,669 | 1,725 | 1,652 | 1,711 | -53 | -3% | 362,300 |
| 2022/01/28 | 1,761 | 1,767 | 1,736 | 1,764 | +20 | +1.1% | 164,200 |
| 2022/01/27 | 1,805 | 1,815 | 1,732 | 1,744 | -49 | -2.7% | 158,000 |
| 2022/01/26 | 1,770 | 1,807 | 1,770 | 1,793 | +24 | +1.4% | 68,200 |
| 2022/01/25 | 1,823 | 1,823 | 1,760 | 1,769 | -53 | -2.9% | 102,400 |
| 2022/01/24 | 1,773 | 1,824 | 1,771 | 1,822 | +22 | +1.2% | 102,900 |
| 2022/01/21 | 1,781 | 1,800 | 1,772 | 1,800 | -3 | -0.2% | 88,900 |
| 2022/01/20 | 1,798 | 1,822 | 1,787 | 1,803 | +22 | +1.2% | 70,300 |
| 2022/01/19 | 1,806 | 1,824 | 1,773 | 1,781 | -54 | -2.9% | 139,000 |
| 2022/01/18 | 1,852 | 1,861 | 1,826 | 1,835 | -14 | -0.8% | 78,900 |
| 2022/01/17 | 1,874 | 1,875 | 1,843 | 1,849 | -25 | -1.3% | 94,800 |
| 2022/01/14 | 1,900 | 1,900 | 1,856 | 1,874 | +10 | +0.5% | 192,400 |
| 2022/01/13 | 1,912 | 1,912 | 1,864 | 1,864 | -48 | -2.5% | 102,000 |
| 2022/01/12 | 1,906 | 1,914 | 1,893 | 1,912 | +34 | +1.8% | 75,900 |
| 2022/01/11 | 1,874 | 1,878 | 1,855 | 1,878 | +22 | +1.2% | 66,500 |
| 2022/01/07 | 1,867 | 1,880 | 1,843 | 1,856 | ±0 | ±0% | 127,000 |
| 2022/01/06 | 1,887 | 1,895 | 1,856 | 1,856 | -45 | -2.4% | 121,000 |
| 2022/01/05 | 1,947 | 1,947 | 1,900 | 1,901 | -41 | -2.1% | 107,400 |
| 2022/01/04 | 1,941 | 1,945 | 1,917 | 1,942 | +12 | +0.6% | 120,100 |
| 2021/12/30 | 1,927 | 1,936 | 1,916 | 1,930 | ±0 | ±0% | 28,400 |
| 2021/12/29 | 1,906 | 1,930 | 1,901 | 1,930 | +27 | +1.4% | 92,500 |
| 2021/12/28 | 1,906 | 1,906 | 1,880 | 1,903 | +20 | +1.1% | 102,800 |
| 2021/12/27 | 1,897 | 1,905 | 1,883 | 1,883 | -24 | -1.3% | 90,500 |
| 2021/12/24 | 1,911 | 1,913 | 1,897 | 1,907 | -14 | -0.7% | 96,800 |
651～
700
件表示中 / 6826件
類似銘柄と比較する
現在ご覧いただいている「栄研化」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 栄研化 | 232,200円 | +0.4% | -8.4% | 2.28% | 17.95倍 | 1.76倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
| ネクセラファーマ | 121,300円 | +197.7% | - | 0.00% | 49.57倍 | 1.58倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| 杏林製薬 | 151,800円 | +3.2% | +4.5% | 3.43% | 17.44倍 | 0.67倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ＪＣＲファーマ | 67,900円 | -3.7% | -36.7% | 2.95% | 23.03倍 | 1.51倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| サンバイオ | 101,300円 | - | - | 0.00% | - | 51.01倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
市場注目の銘柄
チャート関連のコラム
